Board of Directors:

Stephen R. Ash, M.D. Chairman of the Board of Directors, Director of Research and Development, and Medical Director
Dr. Ash, a co-founder, has been the Chairman of the Board of Directors and the Director, Research and Development of Ash Access Technology, Inc. since its inception and holds the same positions with HemoCleanse, Inc. He has been a practicing physician in internal medicine, specializing in Nephrology, at the Arnett Clinic, Lafayette, Indiana and the Director of Dialysis services at St. Elizabeth Hospital and Home Hospital since 1975. He is also an adjunct Associate Professor of Comparative Medicine at the Department of Veterinary Medicine, Purdue University and has held this position since 1980. From 1975 to 1983, Dr. Ash served as a Research Associate and Director of Hemodialysis Laboratory at the Institute of Interdisciplinary Engineering Studies, Purdue University. He is an author of approximately twenty U.S. patents and nearly one hundred publications in the areas of hemodialysis, peritoneal dialysis, vascular access devices, extracorporeal medical devices, computerized medical charting, and sorbent chemicals. Dr. Ash received a B.A. in physics in 1967 from Northwestern University and an M.D. in 1971 from Kansas University Medical School. Dr. Ash is certified by the American Board of Internal Medicine, Nephrology section, and a Fellow of the American College of Physicians and a Founding Member of the American Society of Diagnostic and Interventional Nephrology (ASDIN).

Joseph H. Broecker  Mr. Broecker is the Chairman and a Managing Director of Periculum Capital Company, LLC, a private investment and merchant banking company concentrating in the Midwestern geographic market.  Periculum places its major emphasis on mergers and acquisitions as well as equity and debt financing for middle market companies.  He was previously Senior Vice President and Managing Director of Investment Banking of NatCity Investments, Inc., which is the securities subsidiary of National City Bank.  National City is a large regional investment banking and brokerage firm.  Mr. Broecker has served in several senior executive capacities in the medical device and diagnostics field with Boehringer Mannheim and its predecessor, Bio-Dynamics, Inc.  Mr. Broecker is also a partner in several venture capital partnerships and serves as a director of a number of public and private companies.  He is a Certified Public Accountant and has a BBA in Business Administration from the University of Notre Dame and an Executive MBA from Indiana University.

Lorelei D. Davis, Ph.D.  Dr. Davis is a Partner of Frantz Medical Ventures, Cleveland Ohio, a Series B investor in Ash Access Technology. In her role with Frantz Medical Ventures, she oversees the investment portfolio and supports portfolio companies through participation on Boards of Directors and Scientific Advisors.  Dr. Davis also holds the position of Vice President, Research and Business Development of Frantz BioMarkers, Cleveland, Ohio. From 1992 through 2004, she held numerous positions with organizations in the medical industry, including LPL Technologies, a startup in cancer diagnostics funded by Frantz, and the Cleveland Clinic Foundation, in the Office of Technology Transfer. Dr. Davis received her B.S. in Zoology from Brigham Young University in 1983 and her Ph.D. in Genetics from the University of North Carolina in 1988.  She was Post-doctoral Fellow with the Imperial Cancer Research Fund in London, England from 1989 to 1992.

Adel Korkor, M.D.  Dr. Adel Korkor is the Medical Director and CEO of Purity Dialysis Center, which provides chronic renal dialysis, services throughout Waukesha County, Wisconsin.  In 1974, Dr. Korkor graduated magna cum laude from Medical College, Damascus University.  He completed his medical residency at the Hahnemann Medical College affiliated hospitals in Trenton, New Jersey.  Dr. Korkor’s first clinical Nephrology Fellowship was at the Eastern Virginia Medical School in Norfolk, Virginia.  A combined clinical and research Nephrology Fellowship at Washington University, Barnes Hospital in St. Louis, Missouri followed.  Dr. Korkor served as an instructor of medicine there for one year before joining the staff at the Medical College of Wisconsin.  At the college he served as an Assistant Professor of Medicine in the Department of Nephrology for six years.  In the Fall of 1987, he established Nephrology Associates.  In addition to his vast clinical experience, Dr. Korkor has published and spoken extensively on topics related to hypertension, kidney disease and metabolic bone disease.

Gary J. Lehman  Mr. Lehman, President and CEO of Fairfield Manufacturing, has joined Ash Access Technology’s Board of Directors as a representative of the Series C investors. He joined Fairfield Manufacturing in 2003 where he led a successful financial restructuring and operational turnaround which resulted in the sale of the business to a European based strategic partner. Prior to joining Fairfield, Mr. Lehman held Senior Executive positions with Philips Electronics NV, ITT Automotive and Federal-Mogul Corporation. He brings extensive experience in Division Management, Operations, Sales and Marketing as well as Strategic Management, Mergers and Acquisitions. He received his B.S. in Industrial Management / Industrial Engineering from Purdue University and an MBA from Case Western Reserve University. He is also the Chairman of the Dean’s Advisory Committee at the Krannert School of Management, Purdue University.

Domenick Treschitta  Mr. Treschitta represents a Bear Stearns private investment fund, a Series B investor in Ash Access Technology.  He has more than 25 years operating experience in the medical industry primarily in sales and marketing.  He helped build Deseret Pharmaceutical Company (now BD Vascular Access) from a startup to a New York Stock Exchange company and was involved in the sale of the Company to Warner Lambert.  Following his work with Deseret, Mr. Treschitta helped build Ballard Medical into a NYSE company.  As Executive VP of Ballard, he built the international sales organization, created the R&D department, negotiated royalty agreements and was involved in major patent litigations against companies infringing Ballard’s intellectual property.  Mr. Treschitta received his B.A. from the University of Connecticut in 1963.

Robert B. Truitt - President and CEO
Mr. Robert Truitt, a co-founder, serves as the President and CEO of Ash Access Technology, Inc. and HemoCleanse, Inc. He is the former President and Chairman of Renal Solutions, Inc. another HemoCleanse, Inc. spin-off. He was General Partner of Indiana Growth Fund I, Ltd., the initial funding source for Ash Access Technology, Inc. and many other small start-up companies. Mr. Truitt is the former principal consultant with Truitt and Associates, a consulting firm created to facilitate and stimulate entrepreneurship by supplying a wide range of management support to small enterprises and new ventures with a primary focus on applied high technology industries. Mr. Truitt spent the period of 1967 to 1982 holding various positions with the Allen-Bradley Company, Rostone Division, a custom-engineered molder of fiberglass-reinforced thermoset plastic component parts, where he started as a Project Engineer in 1967 and was promoted to President in 1974. From 1963 to 1965, Mr. Truitt was a Space Guidance Analyst, Apollo Project, with General Motors, on loan to M.I.T. Mr. Truitt received M.S. and B.S. degrees in Engineering Science from Purdue University and an M.B.A. from Harvard University. He holds a number of affiliations and honors and is a holder of three patents. Mr. Truitt is the husband of Patricia P. Truitt.

Norman R. Weldon, Ph.D.  Dr. Weldon is Managing Director of Partisan Management Group, Inc., an early stage venture capital company that assists with the funding and management of medical device startups. He is also on the Board of two medical device companies he co-founded. Dr. Weldon received his BS in Biochemistry in 1956, MS in Industrial Management in 1962, and PhD in Economics in 1964, all from Purdue University. He has been the CEO of three public companies: CTS Corporation, Cordis Corporation and Corvita Corporation. He was a co-founder of CTS Microelectronics, Inc., Corvita Corporation, Novoste Puerto Rico, Inc., Novoste Corporation and Enable Medical Corporation and he is a director of two mutual funds: New Economy Fund and SmallCap World Fund.